) --

Complete Genomics



) hit a new 52-week low Wednesday as it is currently trading at $2.15, below its previous 52-week low of $2.21 with 211,067 shares traded as of 10:10 a.m. ET. Average volume has been 1.9 million shares over the past 30 days.

Complete Genomics has a market cap of $90.8 million and is part of the

health care

sector and


industry. Shares are down 23.5% year to date as of the close of trading on Tuesday.

Complete Genomics, Inc., a life sciences company, develops and commercializes a DNA sequencing platform for human genome sequencing and analysis.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Complete Genomics as a


. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. You can view the full

Complete Genomics Ratings Report


See all

52-week low stocks

or get investment ideas from our

investment research center